Virtus Fund Advisers’s Aratana Therapeutics, Inc. PETX Stock Holding History

Virtus Fund Advisers’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-2,084	Closed	-$33K	–	2288
2014 Q2	$33K	Buy	+2,084	New	+$29.5K	﹤0.01%	2143

Other funds holding PETX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Virtus Fund Advisers's PETX Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2014, closing a stake of 2,084 shares — an estimated $33K sold.

Virtus Fund Advisers first reported a position in PETX in Q2 2014 and held it in 1 quarter. The position peaked at $33K in Q2 2014. 82 funds tracked by Wall St. Rank hold PETX as of Q3 2014.

Virtus Fund Advisers reported no remaining Aratana Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
Virtus Fund Advisers sold 2,084 Aratana Therapeutics, Inc. shares in Q3 2014, an estimated $33K.
Virtus Fund Advisers first reported a position in Aratana Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
Virtus Fund Advisers's Aratana Therapeutics, Inc. position peaked at $33K in Q2 2014.
82 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.